Astellas is committed to developing treatments for serious, hard-to-treat infections
Despite stable or falling rates for many infections, every year in the EU infectious diseases cause tens of thousands of deaths, many millions of lost working days, and untold pain and suffering.¹
True to our commitment to focus on areas of greatest unmet medical need, the Astellas Anti-Infectives portfolio includes medicines for invasive fungal infections and Clostridium difficile infection (CDI).
CDI is potentially fatal, with symptoms ranging from watery diarrhoea to severe, life-threatening intestinal complications.² In one in ten patients, CDI causes or contributes to intensive care admission or death, or leads to surgery to remove part of the bowel (colectomy).³ The infection is common. In the EU, more than six patients contract CDI per 10,000 bed days4 and it is estimated to cost the region three billion Euros per year.5
Astellas is committed to developing further treatments for serious, hard-to-treat infections.
1.European Center for Disease Prevention and Control. Microbes without borders: Key facts on infectious diseases in Europe. 2007.
2. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009;15:1067–79.
3. Bauer MP, Noretmans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011;377:63–73.
4. Davies KA, Longshaw CM, Davis GL, Ashe S, Ashwin H, Lee F, Wilcox M H. First report from European, multi‐centre, prospective bi‐annual point prevalence study of Clostridium difficile Infection in hospitalised patients with Diarrhoea (EUCLID). ECCMID 2013; Poster: LB-2968
5. European Centre for Disease Prevention. Clostridium difficile infection – basic facts.
Learn more about our therapy areas:
Innovative therapies in preventing organ rejection after transplantation
World-leading approach in R&D to satisfy unmet patient needs in urological conditions
Our commitment is to developing first-in-class and best-in-class therapies
Addressing the complex challenges of serious fungal and bacterial infections
Pioneering treatments that effectively manage chronic pain